Feeds
3807 items (3807 unread) in 74 feeds
Acinar Cell Carcinoma
(40 unread)
Acinic Cell Carcinoma
(50 unread)
Adenoid Cystic Carcinoma
(96 unread)
Adrenal Gland Cancer
(350 unread)
Ampulla Of Vater
(53 unread)
Anal Cancer
(367 unread)
Angiosarcoma
(88 unread)
Appendix Cancer
(50 unread)
Bile Duct Cancer
(400 unread)
Brain and CNS
(353 unread)
Carcinoid
(144 unread)
Endocrine/Neuroendocrine
(453 unread)
Gall Bladder Cancer
(301 unread)
Hemangioendothelioma
(90 unread)
Hepatoblastoma
(50 unread)
Pancreas
(28 unread)
Phyllodes
(17 unread)
PMP and Mucinous Tumors
(22 unread)
Rhabdomyosarcoma
(212 unread)
Sarcoma
(643 unread)
Pancreas (28 unread)
Google - Insulinoma
-
Insulinoma Market – Historic, Current and Future Analysis By 2028 – Industrial IT - Industrial IT
Posted: January 6th, 2022, 5:30am GMT
-
Lng Bunkering Market Future Prospects 2027 | – Johnson & Johnson Novartis Pfizer Teva Pharmaceutical Industries Abcam plc – Industrial IT - Industrial IT
Posted: January 5th, 2022, 10:09am GMT
-
Insulinoma Treatment Market 2021-2027: Size, Share, Upcoming Trends, Demand –Cmr Fuel Cells PLC, Polyfuel Inc, SFC Power – Industrial IT - Industrial IT
Posted: January 5th, 2022, 10:09am GMT
-
GlucaGen side effects: What they are and how to manage them - Medical News Today
Posted: January 5th, 2022, 6:00am GMT
GlucaGen side effects: What they are and how to manage them Medical News Today -
Rezolute : Corporate Presentation – January 2022 - marketscreener.com
Posted: January 4th, 2022, 2:59pm GMT
Rezolute : Corporate Presentation – January 2022 marketscreener.com -
Potential of [11C]UCB-J as a PET tracer for islets of Langerhans | Scientific Reports - Nature.com
Posted: December 28th, 2021, 8:30am GMT
-
Insulinoma Market Research 2020-2026: Applications, Type, Deployment, Organization Size, Verticals Forecast – LSMedia - LSMedia
Posted: December 24th, 2021, 11:00am GMT
-
Trending Report of Hip Arthroscopy Market – Drivers, Strategies, Applications and Competitive Landscape 2026 – LSMedia - LSMedia
Posted: December 24th, 2021, 10:54am GMT
-
Spotlight on NLRP3 inflammasome | JIR - Dove Medical Press
Posted: December 20th, 2021, 9:58am GMT
Spotlight on NLRP3 inflammasome | JIR Dove Medical Press -
Meningioma: Causes and Risk Factors - Verywell Health
Posted: December 14th, 2021, 6:00am GMT
Meningioma: Causes and Risk Factors Verywell Health -
Von Hippel-Lindau Disease: Overview and More - Verywell Health
Posted: November 22nd, 2021, 6:00am GMT
Von Hippel-Lindau Disease: Overview and More Verywell Health -
How an Insulinoma Is Treated - Verywell Health
Posted: October 15th, 2021, 5:00am GMT
How an Insulinoma Is Treated Verywell Health -
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia - Business Wire
Posted: August 23rd, 2021, 5:00am GMT
-
Evaluation of the expression of hexokinase 1, glucokinase, and insulin by canine insulinoma cells maintained in short-term culture - American Veterinary Medical Association
Posted: February 1st, 2021, 6:00am GMT
Evaluation of the expression of hexokinase 1, glucokinase, and insulin by canine insulinoma cells maintained in short-term culture American Veterinary Medical Association -
Diabetic Shock and Insulin Reactions: Causes, Symptoms, and Treatments - WebMD
Posted: July 17th, 2020, 5:00am GMT
-
Pancreatic Neuroendocrine Tumor: Types, Symptoms, Outlook & More - Healthline
Posted: September 27th, 2017, 10:11pm GMT
-
Was Steve Jobs' genius also a fatal flaw? - BBC News
Posted: March 8th, 2012, 6:00am GMT
PubMed - Insulinoma
-
Adult-Onset Focal Nesidioblastosis With Nodular Formation Mimicking Insulinoma
Fetched: January 14th, 2022, 5:01am GMT by Shunsuke Doi
J Endocr Soc. 2021 Dec 11;6(1):bvab185. doi: 10.1210/jendso/bvab185. eCollection 2022 Jan 1.
ABSTRACT
Nesidioblastosis is defined as the neoformation of the islets of Langerhans from the pancreatic ductal epithelium and is recognized as the most common cause of hyperinsulinemic hypoglycemia in infants. We herein report an extremely rare case of adult-onset focal nesidioblastosis with the unusual feature of hyperplastic nodular formation. A 55-year-old woman was admitted to our hospital for a tumor detected in the body of the pancreas by magnetic resonance imaging screening. Laboratory examinations showed a high insulin level in the blood. Contrast-enhanced computed tomography and the selective arterial calcium injection test suggested the presence of multiple insulinomas in the body and tail of the pancreas, and, thus, the patient underwent distal pancreatectomy. A histopathological examination of the tumor in the body of the pancreas showed the nodular hyperplasia of islet-like cell clusters. In addition, many small intralobular ductules and islet cells appeared to be budding from the proliferating ductal epithelium, forming "ductuloinsular complexes". No other abnormal lesion was detected in the remainder of the pancreas. The histopathological diagnosis was focal nesidioblastosis. The patient has remained free of the recurrence of hypoglycemic episodes for more than 31 months. The present case of rare adult-onset focal nesidioblastosis with hyperplastic nodular formation was preoperatively identified as an apparent pancreatic tumor mimicking insulinoma. Nesidioblastosis and insulinoma need to be considered in cases of hyperinsulinemic hypoglycemia, even in adult patients.
PMID:35024540 | PMC:PMC8743044 | DOI:10.1210/jendso/bvab185
-
Reply to Kawasaki et al Regarding "Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast"
Fetched: January 11th, 2022, 5:01am GMT by Mieke R Van Bockstal
Int J Surg Pathol. 2022 Jan 10:10668969211070173. doi: 10.1177/10668969211070173. Online ahead of print.
NO ABSTRACT
PMID:35001694 | DOI:10.1177/10668969211070173
-
SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors
Fetched: January 9th, 2022, 5:01am GMT by Lu Yu
Diagn Pathol. 2022 Jan 7;17(1):2. doi: 10.1186/s13000-021-01186-0.
ABSTRACT
BACKGROUND: Synaptophysin (SYN), chromogranin A (CGA), CD56 and insulinoma-associated protein 1 (INSM1) are proposed neuroendocrine (NE) markers used for diagnosis of pulmonary NE tumors. These NE markers have been identified in subsets of non-NE tumors requiring differential diagnosis, thus we sought to explore new NE markers.
METHODS: We evaluated the immunohistochemical expression of SOX11, a transcription factor involved in neurogenesis, in pulmonary NE tumors and large cell carcinomas (LCCs).
RESULTS: We found that SOX11 showed a sensitivity similar to INSM1 and CGA, and less than SYN and CD56 in small cell lung carcinomas (SCLCs) and large cell neuroendocrine carcinomas (LCNECs). While SOX11 is more specific than the other four markers for diagnosis of high-grade neuroendocrine carcinomas (HG-NECs) because 1) None of LCCs (0/63), the most challenging non-NE tumor type for differential diagnosis due to overlapped morphology with LCNECs displayed SOX11 positivity. While expression of at least one of SYN, CGA, CD56 or INSM1 was identified in approximately 60% (18/30) of LCCs. 2) SOX11 was only expressed in 1 of 37 carcinoid tumors in contrast to diffuse expression of SYN, CGA, CD56 and INSM1. In HG-NECs, we noticed that SOX11 was a good complementary marker for SCLC diagnosis as it was positive in 7 of 18 SYN-/CGA-/CD56- SCLCs and 3 of 8 SYN-/CGA-/CD56-/INSM1- SCLCs, and SOX11 positivity in 4 of 6 SYN-/CGA-/CD56- cases previously diagnosed as LCCs with NE morphology provides additional evidence of NE differentiation for reclassification into LCNECs, which was further confirmed by electromicroscopical identification of neurosecretory granules. We also found SOX11 expression cannot predict the prognosis in patients with HG-NECs.
CONCLUSIONS: Therefore, SOX11 is a useful complementary transcriptional NE marker for diagnosis and differential diagnosis of SCLC and LCNEC.
PMID:34996493 | PMC:PMC8742448 | DOI:10.1186/s13000-021-01186-0
-
Practical Clinical Applications of Islet Autoantibody Testing in Type 1 Diabetes
Fetched: January 9th, 2022, 5:01am GMT by William E Winter
J Appl Lab Med. 2022 Jan 5;7(1):197-205. doi: 10.1093/jalm/jfab113.
ABSTRACT
BACKGROUND: The distinction between type 1 diabetes (T1D) and type 2 diabetes (T2D) is extremely important for the choice of therapy, body weight and dietary management, screening for coexistent autoimmune diseases and comorbidities, anticipated prognosis, and risk assessment in relatives. Not uncommonly, the presentation of the patient may not allow an unambiguous discrimination between T1D and T2D. To help resolve this challenge, the detection of islet autoantibodies can support the diagnosis of T1D.
CONTENT: The presence of islet autoantibodies in a person with diabetes indicates an autoimmune etiology therefore establishing the diagnosis of T1D. Presently 5 islet autoantibodies are available for routine clinical use: islet cell cytoplasmic autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibodies (GADA), insulinoma associated-2 autoantibodies (IA-2A), and zinc transporter-8 autoantibodies (ZnT8A). There are caveats to the selection of which islet autoantibodies should be measured. Islet autoantibodies can also predict the development of T1D. Therefore, once safe and effective therapies are available to prevent T1D, islet autoantibody testing is expected to become a routine part of medical practice. A very rare cause of autoimmune diabetes is the type B insulin resistance syndrome resulting from antagonistic autoantibodies to the insulin receptor. Rarely hypoglycemia can result from agonistic insulin receptor autoantibodies, or high-titer IAA causing the autoimmune insulin syndrome (i.e., Hirata disease).
SUMMARY: In summary, autoimmune causes of dysglycemia are increasing in clinical importance requiring the scrutiny of laboratorians. The determination of islet autoantibodies can greatly aid in the diagnosis and the prediction of T1D.
PMID:34996067 | DOI:10.1093/jalm/jfab113
-
The correlation between amylin and insulin by treatment with 2-deoxy-D-glucose and/or mannose in rat insulinoma ins-1E cells
Fetched: January 7th, 2022, 5:02am GMT by H S Kim
J Physiol Pharmacol. 2021 Aug;72(4). doi: 10.26402/jpp.2021.4.03. Epub 2021 Dec 31.
ABSTRACT
Amylin or islet amyloid polypeptide (IAPP) is a peptide synthesized and secreted with insulin by the pancreatic β-cells. A role for amylin in the pathogenesis of type 2 diabetes (T2D) by causing insulin resistance or inhibiting insulin synthesis and secretion has been suggested by in vitro and in vivo studies. These studies are consistent with the effect of endogenous amylin on pancreatic βcells to modulate and/or restrain insulin secretion. Here, we reported the correlation between amylin and insulin in rat insulinoma INS-1E cells by treating 2-deoxy-D-glucose (2-DG) and/or mannose. Cell viability was not affected by 24 h treatment with 2-DG and/or mannose, but it was significantly decreased by 48 h treatment with 5 and 10 mM 2-DG. in the 24 h treatment, the synthesis of insulin in the cells and the secretion of insulin into the media showed a significant inverse association. in the 48-h treatment, amylin synthesis vs. the secretion and insulin synthesis vs. the secretion showed a significant inverse relation. The synthesis of amylin vs. insulin and the secretion of amylin vs. insulin showed a significant inverse relationship. The p-ERK, antioxidant enzymes (Cu/Zn-superoxide dismutase (SOD), Mn-SOD, and catalase), and endoplasmic reticulum (ER) stress markers (cleaved caspase-12, CHOP, p-SAPK/JNK, and BiP/GRP78) were significantly increased or decreased by the 24 h and 48 h treatments. These data suggest the relative correlation to the synthesis of amylin by cells vs. the secretion into the media, the synthesis of amylin vs. insulin, and the secretion of amylin vs. insulin under 2-DG and/or mannose in rat insulinoma INS-1E cells. Therefore, these results can provide primary data for the hypothesis that the amylin-insulin relationships may be involved with the human amylin toxicity in pancreatic beta cells.
PMID:34987125 | DOI:10.26402/jpp.2021.4.03
-
Multiple Endocrine Neoplasia Type 1
Fetched: December 30th, 2021, 5:01am GMT by Carolina R.C. Pieterman
2021 Dec 22. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
ABSTRACT
Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare autosomal dominantly inherited endocrine tumor predisposition syndrome, caused by mutations in the MEN1 gene. Cardinal manifestations are primary hyperparathyroidism (pHPT), pituitary adenomas (PA), and neuroendocrine tumors (NETs) of the pancreas (PanNET) and duodenum. Other manifestations are NETs of thymus, lung, and stomach, adrenal tumors, and an increased breast cancer risk in women. Malignant NETs are the most important cause of disease-related mortality, mainly NF-PanNETs, gastrinomas and thymus NETs. MEN1 can be diagnosed genetically and a clinical diagnosis in patients with negative comprehensive testing has been debated. Timely recognition of MEN1, referral for genetic testing and swift cascade screening is essential. MEN1-related pHPT (penetrance >95%) is a multiglandular disease and recurrence after initial operation is to be expected. Subtotal parathyroidectomy is the preferred initial operation. Prolactinomas are the most prevalent PA in MEN1, followed by non-functioning (NF) PAs. Treatment and treatment results do not differ from sporadic PAs. Life-time penetrance of duodenopancreatic NETs is >80%. NF-PanNETs are most frequent, followed by gastrinomas and insulinomas. Surgical resection is the mainstay of treatment, and is indicated in non-gastrinoma functional PanNETs and NF-PanNETs >2cm or with progression during follow-up. No consensus exists on the surgical treatment of MEN1-related gastrinoma. MEN1-related dpNETs are currently detected at earlier stages and more indolent small dpNETs are seen. The main challenge is to identify patients at risk for an aggressive disease course. Thymic NETs (2-8%) occur predominantly in males and have a poor prognosis. Bronchopulmonary NETs are more frequent than previously thought, occur in both sexes, and are usually indolent although cases with a deviant progressive course occur. Adrenal tumors are mostly indolent non-functioning adenomas, but adrenocortical carcinomas and pheochromocytomas do occur. Women with MEN1 have an increased (RR 2.8) risk of breast cancer, at a younger age than the general population. Given the complexity of the disease, it is strongly advised that patients, whenever possible, be followed and treated in centers of expertise. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.
-
High Mast Cell Density Predicts a Favorable Prognosis in Patients with Pancreatic Neuroendocrine Neoplasms
Fetched: December 29th, 2021, 5:01am GMT by Shengwei Mo
Neuroendocrinology. 2021 Dec 28. doi: 10.1159/000521651. Online ahead of print.
ABSTRACT
INTRODUCTION: Mast cells are involved in allergic diseases, immune regulation, and tumor microenvironment modulation, with both pro- and anti-tumorigenic functions, and could serve as a prognostic factor in various cancers. However, their potential role in pancreatic neuroendocrine neoplasms (PanNENs) is largely unknown. Here, our aim was to investigate the presence of mast cells in PanNENs and evaluate their association with clinicopathological parameters and other common tumor-infiltrating immune cells.
METHODS: Tissue microarrays containing PanNEN samples from 187 patients were constructed and stained immunohistochemically for CD117, CD15, CD68, CD3, CD4, and CD8. Immune cells were counted from four high-power fields (HPFs; 400×) at maximal concentrations, and the mean counts were calculated per HPF. The cut-off values were set by X-tile.
RESULTS: The median (interquartile range) counts of CD117+ mast cells, CD15+ neutrophils, CD68+ macrophages, CD3+ T cells, and CD4+ T cells were 3.5 (2.0-6.0), 3.0 (1.3-6), 3.8 (2.5-5.8), 13 (8.0-24.0), 2.0 (1.0-4.0)/HPF, respectively. CD8+ T cells were not detected. The cut-off values for these immune cells were 1.5/HPF, 6/HPF, 4.8/HPF, 32.5/HPF, and 2/HPF, respectively. Low mast cell density was correlated with higher grades, non-insulinoma, and advanced stages. Moreover, high mast cell infiltration was associated with elevated CD4+ T cell and CD15+ neutrophil counts. Multivariate analysis revealed that high mast cell density was an independent predictor of prolonged progression-free survival in the entire cohort, in pancreatic neuroendocrine tumors, and in intermediate-grade, non-insulinoma, and advanced stage subgroups.
CONCLUSIONS: These findings suggest a protective role of mast cells in PanNENs.
PMID:34963123 | DOI:10.1159/000521651
-
Letter to Editor Regarding "Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast" by Seijnhaeve et al
Fetched: December 28th, 2021, 5:01am GMT by Tomonori Kawasaki
Int J Surg Pathol. 2021 Dec 27:10668969211067764. doi: 10.1177/10668969211067764. Online ahead of print.
NO ABSTRACT
PMID:34955068 | DOI:10.1177/10668969211067764
-
INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View
Fetched: December 25th, 2021, 5:01am GMT by Zahra Maleki
Diagnostics (Basel). 2021 Nov 23;11(12):2172. doi: 10.3390/diagnostics11122172.
ABSTRACT
Insulinoma-associated protein 1 (INSM1) has been considered as a novel immunostain for neuroendocrine tumors (NETs) and is hypothesized to be more reliable than first-generation NET biomarkers, such as CGA (chromogranin A), SYP (synaptophysin) and CD56 (neural cell adhesion molecule). In this review, we summarize existing literature on INSM1's reliability as an immunostain for detection of various NETs, its results in comparison to first-generation NET biomarkers, and its expression in both non-NETs and benign tissues/cells on cytology specimens (cell blocks/smears).
PMID:34943408 | PMC:PMC8700458 | DOI:10.3390/diagnostics11122172
-
Artificial Cell Encapsulation for Biomaterials and Tissue Bio-Nanoengineering: History, Achievements, Limitations, and Future Work for Potential Clinical Applications and Transplantation
Fetched: December 24th, 2021, 5:01am GMT by Armin Mooranian
J Funct Biomater. 2021 Nov 30;12(4):68. doi: 10.3390/jfb12040068.
ABSTRACT
Pancreatic β-cell loss and failure with subsequent deficiency of insulin production is the hallmark of type 1 diabetes (T1D) and late-stage type 2 diabetes (T2D). Despite the availability of parental insulin, serious complications of both types are profound and endemic. One approach to therapy and a potential cure is the immunoisolation of β cells via artificial cell microencapsulation (ACM), with ongoing promising results in human and animal studies that do not depend on immunosuppressive regimens. However, significant challenges remain in the formulation and delivery platforms and potential immunogenicity issues. Additionally, the level of impact on key metabolic and disease biomarkers and long-term benefits from human and animal studies stemming from the encapsulation and delivery of these cells is a subject of continuing debate. The purpose of this review is to summarise key advances in this field of islet transplantation using ACM and to explore future strategies, limitations, and hurdles as well as upcoming developments utilising bioengineering and current clinical trials.
PMID:34940547 | PMC:PMC8704355 | DOI:10.3390/jfb12040068
-
Two new scopadulane diterpenoids from Scoparia dulcis attenuated palmitate-induced viability in MIN6 cells
Fetched: December 23rd, 2021, 5:01am GMT by Lin Dong
Fitoterapia. 2021 Nov;155:105051. doi: 10.1016/j.fitote.2021.105051. Epub 2021 Oct 9.
ABSTRACT
Two new scopadulane diterpenoids, termed Scopadulcic acids D (1, SDD) and E (2, SDE), together with two known analogues (3 and 4) were isolated from Scoparia dulcis. Their structures were elucidated by comprehensive spectroscopic analysis. The absolute configurations of 1 and 2 were determined by calculated electronic circular dichroism (ECD). Meanwhile, X-ray crystallographic analysis was applied to determine the absolute configuration of 1. All compounds were tested for their effect on attenuating palmitate-induced viability at the concentrations of 25 and 50 μM. The results showed that they significantly attenuated the palmitate-induced viability in MIN6 cells.
PMID:34637884 | DOI:10.1016/j.fitote.2021.105051